{"nctId":"NCT01218958","briefTitle":"ALK21-003: Study of Medisorb® Naltrexone (VIVITROL®) in Alcohol-Dependent Adults","startDateStruct":{"date":"2002-02"},"conditions":["Alcoholism"],"count":624,"armGroups":[{"label":"Medisorb naltrexone 190 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Medisorb naltrexone 190 mg"]},{"label":"Medisorb naltrexone 380 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Medisorb naltrexone 380 mg"]},{"label":"Placebo for Medisorb naltrexone 190 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo matching Medisorb naltrexone 190 mg"]},{"label":"Placebo for Medisorb naltrexone 380 mg","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo matching Medisorb naltrexone 380 mg"]}],"interventions":[{"name":"Medisorb naltrexone 190 mg","otherNames":["naltrexone for extended-release injectable suspension"]},{"name":"Medisorb naltrexone 380 mg","otherNames":["VIVITROL 380 mg","naltrexone for extended-release injectable suspension"]},{"name":"Placebo matching Medisorb naltrexone 190 mg","otherNames":[]},{"name":"Placebo matching Medisorb naltrexone 380 mg","otherNames":["Placebo matching VIVITROL 380 mg"]}],"eligibilityModule":{"eligibilityCriteria":"Primary Inclusion Criteria:\n\n* Diagnosis of alcohol dependence based on Diagnostic and Statistical Manual of Mental Disorders, 4th Ed. (DSM-IV) criteria\n* Male or non-pregnant, non-lactating female\n* Able to provide TimeLine Follow-Back (TLFB) alcohol consumption information for 90-day period before detoxification and/or screening\n* At least 2 episodes of heavy alcohol drinking per week during the 30 days before detoxification and/or screening\n* Negative urine toxicological screen for opiates on day of randomization\n* Noncustodial, stable residence and phone plus 1 contact with verifiable address and phone\n\nPrimary Exclusion Criteria:\n\n* Evidence of hepatic failure including: ascites, prolonged prothrombin time (PT) (international normalized ratio \\[INR\\] ≥1.7), bilirubin \\>10% above upper limit of normal (ULN) and/or esophageal variceal disease\n* Active hepatitis and/or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) higher than 3xULN\n* History of pancreatitis\n* Major depression with suicidal ideation, psychosis, bipolar disorder, or psychiatric disorders that would compromise subject's ability to complete the study\n* Current dependence (within past year) per DSM-IV criteria to benzodiazepines, opioids or cocaine\n* Use of benzodiazepines and/or Ambien® (zolpidem tartrate) within 7 days prior to first dose of study medication\n* Greater than 7 days inpatient treatment for substance use disorders within 30 days of randomization\n* Use of any opioids and/or methadone within 14 days of screening, or likely requiring opioid therapy during study period\n* Use of oral naltrexone or disulfiram within 14 days of screening\n* Known intolerance and/or hypersensitivity to naltrexone, carboxymethylcellulose, or polylactide-co-glycolide (PLG)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Heavy Drinking Days Over the Treatment Period","description":"Drinking rates were assessed from participants' self-reports using the validated Timeline Follow-Back (TLFB) method. Using a TLFB calendar, participants reported the number of days they had consumed alcohol along with the amount they consumed on each day. A heavy drinking day was defined as ≥5 drinks/day for men and ≥4 drinks/day for women.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.75","spread":null},{"groupId":"OG001","value":"10.23","spread":null},{"groupId":"OG002","value":"19.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting at Least 1 Treatment-emergent Adverse Event (TEAE)","description":"A TEAE is any adverse event, whether or not considered drug-related, that develops or worsens in severity after study drug administration begins (ie, from the first administration through the end of the follow-up period).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"190","spread":null},{"groupId":"OG001","value":"187","spread":null},{"groupId":"OG002","value":"181","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":10,"n":210},"commonTop":["Nausea","Headache NOS","Fatigue","Insomnia","Nasopharyngitis"]}}}